Andrew J Bishop1, Jace P Landry2, Christina L Roland2, Ravin Ratan3, Barry W Feig2, Bryan S Moon4, Maria A Zarzour3, Wei-Lien Wang5, Alexander J Lazar5,6, Valerae O Lewis4, Keila E Torres2, B Ashleigh Guadagnolo1,7. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Orthopedic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: The objective of this study was to evaluate treatment outcomes for patients with desmoid tumors (DTs) receiving local therapy with surgery alone, radiation therapy (RT) alone, or combined modality therapy (RT and surgery). METHODS: This was a cross-sectional cohort study of 412 patients with nonmesenteric DTs who received local therapy at the authors' institution between 1965 and 2018. RESULTS: The median follow-up time was 95 months (range, 1-509 months). Local recurrence occurred in 127 patients (31%) at a median time of 21 months (interquartile range, 12-38 months). The 5-year local control (LC) rate was 67%. Patient or tumor factors that were significantly associated with poorer 5-year LC in a multivariable analysis included an age ≤ 30 years (57% vs 75% for an age > 30 years; hazard ratio [HR], 1.73; P = .004), an extremity location (57% vs 71% for a nonextremity location; HR, 1.77; P = .004), and large tumors (59% for >10 cm [HR, 2.17; P = .004] and 65% for 5.1-10 cm [HR, 1.71; P = .02] vs 76% for ≤5 cm). Subset analyses of these high-risk patients revealed no local therapy strategy to be superior for young patients ≤ 30 years old (HR for surgery, 1.42; P = .33; HR for RT, 1.36; P = .38) or for large tumors > 10 cm (HR for surgery, 1.55; P = .46; HR for RT, 0.91; P = .91). However, for patients with extremity tumors, surgery alone was significantly associated with inferior LC (HR for surgery, 5.15; P < .001; HR for RT, 1.51; P = .38). CONCLUSIONS: Local therapy provides durable tumor control in the majority of patients with DTs. However, young patients, patients with an extremity location, and patients with large tumors are at increased risk of recurrence. When active treatment is indicated, systemic therapy should perhaps be considered as a first-line option in these high-risk subsets. Prospective multi-institutional studies evaluating this strategy are warranted.
BACKGROUND: The objective of this study was to evaluate treatment outcomes for patients with desmoid tumors (DTs) receiving local therapy with surgery alone, radiation therapy (RT) alone, or combined modality therapy (RT and surgery). METHODS: This was a cross-sectional cohort study of 412 patients with nonmesenteric DTs who received local therapy at the authors' institution between 1965 and 2018. RESULTS: The median follow-up time was 95 months (range, 1-509 months). Local recurrence occurred in 127 patients (31%) at a median time of 21 months (interquartile range, 12-38 months). The 5-year local control (LC) rate was 67%. Patient or tumor factors that were significantly associated with poorer 5-year LC in a multivariable analysis included an age ≤ 30 years (57% vs 75% for an age > 30 years; hazard ratio [HR], 1.73; P = .004), an extremity location (57% vs 71% for a nonextremity location; HR, 1.77; P = .004), and large tumors (59% for >10 cm [HR, 2.17; P = .004] and 65% for 5.1-10 cm [HR, 1.71; P = .02] vs 76% for ≤5 cm). Subset analyses of these high-risk patients revealed no local therapy strategy to be superior for young patients ≤ 30 years old (HR for surgery, 1.42; P = .33; HR for RT, 1.36; P = .38) or for large tumors > 10 cm (HR for surgery, 1.55; P = .46; HR for RT, 0.91; P = .91). However, for patients with extremity tumors, surgery alone was significantly associated with inferior LC (HR for surgery, 5.15; P < .001; HR for RT, 1.51; P = .38). CONCLUSIONS: Local therapy provides durable tumor control in the majority of patients with DTs. However, young patients, patients with an extremity location, and patients with large tumors are at increased risk of recurrence. When active treatment is indicated, systemic therapy should perhaps be considered as a first-line option in these high-risk subsets. Prospective multi-institutional studies evaluating this strategy are warranted.
Authors: Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz Journal: N Engl J Med Date: 2018-12-20 Impact factor: 91.245
Authors: Kirsi Santti; Annette Beule; Laura Tuomikoski; Mikko Rönty; Anna-Stina Jääskeläinen; Kauko Saarilahti; Hanna Ihalainen; Maija Tarkkanen; Carl Blomqvist Journal: Strahlenther Onkol Date: 2017-01-02 Impact factor: 3.621
Authors: Winan J van Houdt; Olga Husson; Alisha Patel; Robin L Jones; Myles J F Smith; Aisha B Miah; Christina Messiou; Eleonor Moskovic; Omar Al-Muderis; Charlotte Benson; Shane Zaidi; Alison Dunlop; Dirk C Strauss; Andrew J Hayes; Winette T A van der Graaf Journal: Ann Surg Oncol Date: 2019-09-17 Impact factor: 5.344
Authors: Arie J Verschoor; Anne-Marie Cleton-Jansen; Pauline Wijers-Koster; Cheryl M Coffin; Alexander J Lazar; Remi A Nout; Brian P Rubin; Hans Gelderblom; Judith V M G Bovée Journal: Am J Surg Pathol Date: 2015-12 Impact factor: 6.394
Authors: B Ashleigh Guadagnolo; Gunar K Zagars; Matthew T Ballo; Sara S Strom; Raphael E Pollock; Robert S Benjamin Journal: Cancer Date: 2008-07-15 Impact factor: 6.860
Authors: James E Bates; Christopher G Morris; Nicole M Iovino; Michael Rutenberg; Robert A Zlotecki; C Parker Gibbs; Mark Scarborough; Daniel J Indelicato Journal: Int J Radiat Oncol Biol Phys Date: 2017-12-21 Impact factor: 7.038
Authors: Laura Wirth; Alexander Klein; Andrea Baur-Melnyk; Thomas Knösel; Lars H Lindner; Falk Roeder; Volkmar Jansson; Hans Roland Dürr Journal: BMC Musculoskelet Disord Date: 2018-01-05 Impact factor: 2.362
Authors: Brigitta G Baumert; Martin O Spahr; Arthur Von Hochstetter; Sylvie Beauvois; Christine Landmann; Katrin Fridrich; Salvador Villà; Michael J Kirschner; Guy Storme; Peter Thum; Hans K Streuli; Norbert Lombriser; Robert Maurer; Gerhard Ries; Ernst-Arnold Bleher; Alfred Willi; Juerg Allemann; Ulrich Buehler; Hugo Blessing; Urs M Luetolf; J Bernard Davis; Burkhardt Seifert; Manfred Infanger Journal: Radiat Oncol Date: 2007-03-07 Impact factor: 3.481